BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 23, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2018

View Archived Issues

Study investigates IL-6 monoclonal antibody as a treatment for depression

Read More

Phase I data presented for T cells expressing an anti-CD19 CAR

Read More

ITTP demonstrates initial evidence of antitumoral activity in first-in-human trial

Read More

NovImmune presents data supporting approval of emapalumab for hemophagocytic lymphohistiocytosis

Read More

Phase IIb results for pimodivir alone or in combination with oseltamivir for seasonal influenza A

Read More

LncRNAs are gene trainers

Read More

Zinc plus its transporter kill resistant bacteria

Read More

Novel proteolysis-targeting chimeras degrading FLT3 and FAK

Read More

Fimepinostat may sensitize FLT3/ITD acute myeloid leukemia to gilteritinib

Read More

Metabolic strategy could tackle HIV reservoir, other infections

Read More

Carmot initiates phase I study of CT-868

Read More

Surface Oncology reduces scope of CD47 program SRF-231

Read More

Apexigen and with Columbia University Irving Medical Center collaborate on new phase II trial

Read More

Topline data presented from phase I studies of LX-2761

Read More

INmune Bio cleared to begin phase I study of INKmune in ovarian cancer

Read More

DWTI announces results of phase I/IIa study of H-1337

Read More

Novel anti-BMP6 targeted antibody reduces the need for EPO in anemia of chronic disease models

Read More

PASD1 found as immunotherapeutic target in colorectal cancer

Read More

FDA grants permission to initiate first-in-human study of ASN-008

Read More

Kalytera reports first cohort interim data from phase II trial of CBD in acute GvHD

Read More

Trial of TG-4001 with avelumab for HPV16-positive cancer advances into phase II

Read More

Bevespi Aerosphere approved in Europe for COPD

Read More

OSE-127 begins first-in-human trial for treatment of inflammatory autoimmune diseases

Read More

First patients enrolled in phase II SHIELD study of DAV-132

Read More

FDA clears Sirnaomics to begin phase II study of STP-705 for nonmelanoma skin cancer

Read More

Pfizer to discontinue STRIVE study of S. aureus vaccine due to futility

Read More

ARCHES study of Xtandi in metastatic hormone-sensitive prostate cancer meets primary endpoint

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 22, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 22, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing